View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
April 23, 2021updated 08 Feb 2022 1:36pm

Over $4.8bn revenue lost in the orthopaedic market in 2020 due to Covid-19

Last year, the impact of Covid-19 on the orthopaedic market was pronounced. According to GlobalData analysis, the orthopaedic market was worth over $48.4bn prior to Covid-19. The market decreased by around 10% to $43.6bn last year, affected by lower levels of elective procedures.

By GlobalData Healthcare

Last year, the impact of Covid-19 on the orthopaedic market was pronounced. According to GlobalData analysis, the orthopaedic market was worth over $48.4bn prior to Covid-19. The market decreased by around 10% to $43.6bn last year, affected by lower levels of elective procedures.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Twelve-month revenue from Zimmer Biomet declined by 12% to around $7bn last year, while Orthopedics’ revenue from Johnson and Johnson decreased by 12.2% to nearly $7.8bn. Stryker Orthopedics’ organic net sales decreased by 8.1% last year, including 6.6% from decreased unit volume and 1.5% from lower prices. Smith and Nephew reported a revenue loss of around 13% for its orthopaedics and sports medicine business. As the first quarter of 2021 saw continued pressure from Covid-19 and its impact on the recovery of elective procedures, GlobalData expects that it will take the rest of the year to return to pre-pandemic levels for elective orthopaedic surgeries globally.

To fight against the recession, major players have reconstructed their core businesses. For example, Zimmer Biomet recently announced that it would spin off its spine and dental businesses to focus its resources on the hip, knee and trauma markets. Last year, Stryker acquired Wright Medical to expand the product portfolios and customer bases of its trauma, foot and ankle and upper extremities businesses. Smith and Nephew acquired Integra LifeSciences’ Extremity Orthopaedics business to strengthen the extremities business, which is among the fastest-growing segments in orthopaedics.

Despite the unprecedented challenges of the pandemic, most orthopaedic manufacturers have invested heavily in robotic systems. Last year, Zimmer Biomet sold more than 300 robotic surgical assistant (ROSA) knee systems, with $100m in gross revenue. Its ROSA partial knee system recently received US Food and Drug Administration (FDA) clearance for robotically assisted partial knee replacement surgeries. The company expects to launch ROSA Hip by the end of this year.

Stryker’s Mako has secured regulatory approval in China, Brazil and Russia, while Smith and Nephew’s handheld robotics platform, the CORI, will launch in Europe and India this year. Johnson and Johnson recently received 510(k) FDA clearance for the Velys robotic-assisted solution. GlobalData expects to see strong growth in both the robotic systems and disposable markets, driven by the increase of robotic assisted orthopaedic procedures, with a compound annual growth rate (CAGR) of around 10% from 2021 to 2030.

Covid-19 has accelerated the shift in the site of care, with more procedures, particularly with total joints, taking place in outpatient or ambulatory surgical centres (ASCs) to reduce hospital bed occupancy rates. As a result, more orthopaedic instruments are tailored to meet the needs of ASCs with smaller size and remotely controlled features. In addition, companies like Stryker launched ASC-focused businesses last year to deliver specific solutions to optimise clinical and financial outcomes in ASCs. GlobalData expects this trend to continue in the coming years.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU